Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06665945

The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer

Sponsor: University of Utah

View on ClinicalTrials.gov

Summary

The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.

Key Details

Gender

FEMALE

Age Range

21 Years - Any

Study Type

OBSERVATIONAL

Enrollment

245

Start Date

2025-04-15

Completion Date

2027-12-01

Last Updated

2026-04-09

Healthy Volunteers

Yes

Conditions

Ovarian Cancer

Interventions

DIAGNOSTIC_TEST

Platelet RNA expression

The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.

Study Populations 1 and 2: Women with a Recent Diagnosis of an Ovarian or Pelvic Mass (n=215) Inclusion Criteria: 1. Women aged 21 years or older 2. Diagnosed with any type of ovarian or pelvic mass 3. Treatment naïve for current ovarian cancer (if cancer has been diagnosed) 4. The treating medical provider(s) are planning to perform a biopsy, surgery, or other diagnostic procedure to further evaluate the ovarian or pelvic mass (if not already diagnosed prior to consent) Exclusion Criteria: 1. Any other active malignancy 2. Other diagnosis of any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix. Adjuvant endocrine therapy or other maintenance therapy is allowed. 4. Currently receiving chemotherapy, radiation therapy, or other treatments for ovarian cancer 5. Has already undergone complete ovarian mass resection 6. Unable to provide blood sample Study Population 3: Control Women without Ovarian Cancer (n=30) Inclusion Criteria: 1\. Women aged 21 years or older Exclusion Criteria: 1. Any active malignancy or diagnosis of cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 2. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix 3. Hospitalization or surgery (other than minor surgery such as mole removal) within the last 8 weeks 4. Renal failure (defined as eGFR \< 60 mL/min/1.73m² or on dialysis) 5. Liver failure (defined as having hepatic encephalopathy of any degree, OR moderately severe coagulopathy defined as INR ≥ 1.5, OR known cirrhosis, OR ALT of ≥ 10X ULN, OR total bilirubin of ≥ 3.0 mg/dL, OR diagnosis of liver failure) 6. Decompensated or end-stage heart failure (defined as ACC/AHA Stage C or Stage D heart failure) 7. Poorly controlled diabetes mellitus (defined as a HbA1c \> 9.0%) 8. Venous thrombosis, myocardial infarction, or stroke within the last 8 weeks 9. Currently pregnant or have been pregnant within the last 12 weeks 10. Any blood product transfusion within the last 8 weeks 11. Personal history of ovarian cancer at any time 12. History of bilateral salpingo-oophorectomy 13. History of oophorectomy 14. Unable to provide blood sample

Locations (1)

Huntsman Cancer Institute

Salt Lake City, Utah, United States